SINGAPORE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company,” a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced the launch of its nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China. The Company has partnered with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital as the Company continues to expand its national clinical and logistics network. Thi ...

How much does it cost. >> It is a six-f figureure program. >> Like 100,000 or 500,000 or 800,000 cuz there's a big range.>> Much closer to 100,000 than 500,000. >> That's a lot of money. I mean, what do you get for that. You don't get I mean, you don't live forever.>> Nope. You're getting access to me, a team of a couple other physicians, a strength and conditioning team, a nutrition team, and what you're really getting is a path to help you achieve your goal of living longer and living Better. ...

Core Insights - Klotho Neurosciences, Inc. has allowed its Letter of Intent with Turn Biotechnologies to expire, as the proposed transaction did not align with the company's long-term strategic plan [1][2] - The company will redirect its focus and resources towards advancing its Klotho anti-aging protein research pipeline and developing treatments that promise the greatest value for patients and shareholders [2] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company dedicated to developing innovative, disease-modifying cell and gene therapies utilizing a protein derived from the patented "anti-aging" human Klotho gene [4] - The company aims to transform the treatment of neurodegenerative and age-related disorders, including ALS, Alzheimer's disease, and Parkinson's disease, through its proprietary cell and gene therapy programs [4] Market Context - The longevity medicine market is one of the fastest-growing global sectors, driven by an aging population projected to reach 2.1 billion by 2050 [3] - Healthcare costs are currently at 10% of global GDP and are expected to exceed $47 trillion by 2030, highlighting the significant opportunity in the longevity sector [3]

Financial Data and Key Metrics Changes - In Q2 2025, total revenue declined by 3.6%, with EBITDA and net profit decreasing by 1.6% and 3.8% respectively [27][28][33] - The EBITDA margin for Q2 was 41.6%, while the net profit margin was 30.4% [27][33] - For the first half of 2025, total revenue was down 4.6%, with a 5.3% decline in hospital operation revenue [30][33] Business Line Data and Key Metrics Changes - Revenue from non-Thai patients decreased by 6.6%, while Thai patient revenue slightly declined by 0.2% [27][30] - The outpatient service revenue contribution increased to 51% in the first half of 2025, up from 49% in the same period last year [31] - The government third-party contribution dropped to 14% from 18% in the first half of last year due to lower Middle East revenue [31] Market Data and Key Metrics Changes - Middle Eastern business showed strong growth, with Qatar up 18%, UAE up 46%, Oman up 28%, and Saudi Arabia up 54% [6][7] - The company experienced a decline in revenue from the Indo-China segment, particularly from Cambodia, which was offset by growth in Myanmar and Bangladesh [29][30] - The Chinese market saw a significant reduction in patient arrivals, down by over 30% to 40% year over year due to safety concerns [65][66] Company Strategy and Development Direction - The company is focusing on expanding its cancer care services and enhancing patient experience through new facilities and advanced technologies [88][92] - There is an emphasis on strengthening relationships with key stakeholders and third-party payers to drive growth [84] - The company aims to improve its market position by addressing governance issues and enhancing service quality for Kuwaiti patients [42][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q3 2025, expecting stronger performance compared to the first half of the year [18][26] - The company is cautiously optimistic about the return of Kuwaiti patients and the resolution of past payment issues [46][56] - Management highlighted the importance of addressing safety concerns to regain Chinese patient trust and increase medical tourism [66][70] Other Important Information - The company achieved recognition as one of the best specialized hospitals in Thailand across multiple specialties [77][78] - A successful disease screening campaign generated nearly 96 million baht in revenue within two months [80] - The company is actively investing excess cash into financial assets to capture higher interest income [34][35] Q&A Session Summary Question: What are the expectations for the Kuwaiti market? - Management indicated that discussions with Kuwaiti officials are ongoing, and there is cautious optimism about future collaborations and patient flow [46][56] Question: How is the company addressing the decline in Chinese patient arrivals? - The company is expanding its presence in China and engaging in targeted outreach to rebuild trust and increase referrals [66][70] Question: What are the key initiatives for cancer care expansion? - The company is focusing on comprehensive cancer care, integrating advanced technologies, and enhancing patient experience through new facilities [88][92]